Page 7 - Global Phase News Today

For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

Investegate announcements from Hutchmed China Ltd, HUTCHMED Completes Planned Enrollment of FRESCO-2

A JAK1 selective inhibitor could soon become a standard treatment option for people with atopic dermatitis, according to a new Irish study. The findings

 E-Mail Newly published papers further elucidate the mechanisms underlying pridopidines neuroprotective properties through activation of the Sigma-1 Receptor (S1R). Pridopidine enhances mitochondrial function and reduces mHTT-induced ER stress, which are impaired in HD, mediated by the S1R. Three new peer-reviewed publications highlight pridopidines therapeutic potential and provide data supporting the role of the S1R in neurodegenerative diseases Prilenia Therapeutics B...

Trinity College Dublin and St Jamess Hospital, Dublin clinical trials reported efficacy and safety results of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. This pivotal Global Phase 3 study involved 1,600 patients and took place over a two-year period. Results show the drug to so far be the most effective treatment for atopic dermatitis in clinical trials.

Trial results show upadacitinib to be the most effective treatment for atopic dermatitis The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at the School of Medicine, Trinity College and St Jamess Hospital, Dublin have shown the drug upadacitinib to be the most effective treatment to date for this chronic, relapsing inflammatory conditio...

In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New

Share: In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New York, in Addition to the Previously Reported Varia Ongoing Phase 2 Pilot Study of Ensovibep in Ambulatory Patients Now Expanding Into Second Cohort Two Global Phase 2 and 3 Clinical Studies of Ensovibep on Track for Initiation This Month ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 6, 2021...

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program w...